Batroxobin in combination with anticoagulation may promote venous sinus recanalization in cerebral venous thrombosis: A real-world experience

Jia-Yue Ding1,2 | Li-Qun Pan1,2 | Yan-Yu Hu3 | Gary B. Rajah4 | Da Zhou1,2 | Chao-Bo Bai1,2 | Jing-Yuan Ya1,2 | Zhong-Ao Wang1,2 | Ke-Xin Jin1,2 | Jing-Wei Guan1,2 | Yu-Chuan Ding2,4 | Xun-Ming Ji1,2 | Ran Meng1,2

Summary
Aims: The objective of this study was to evaluate cerebral venous recanalization with magnetic resonance black-blood thrombus imaging (MRBTI) in patients with cerebral venous thrombosis (CVT) who underwent batroxobin treatment in combination with anticoagulation.

Methods: A total of 31 CVT patients were enrolled in this real-world registry study. The patients were divided into batroxobin (n = 21) and control groups (n = 10). In addition to the same standard anticoagulation as in the control group, patients in the batroxobin group underwent intravenous batroxobin for a total of three times.

Results: In the batroxobin group compared with the control group, we found better odds of recanalization degree [adjusted OR (95%CI) of 8.10 (1.61-40.7)] and segment-stenosis attenuation [adjusted OR (95%CI) of 4.48 (1.69-11.9)] with batroxobin treatment. We further noted a higher ratio of patients with the attenuation of stenosis [adjusted OR (95%CI) of 26.4 (1.10-635)]; as well as a higher ratio of segments with stenosis reversion [adjusted OR (95%CI) of 4.52 (1.48-13.8)]. However, neurological deficits between the two groups showed no statistical difference at 90-day follow-up (P > 0.05).

Conclusions: Batroxobin may promote venous sinus recanalization and attenuate CVT-induced stenosis. Further randomized study of this promising drug may be warranted to better delineate the amount of benefit.

KEYWORDS
anticoagulation, batroxobin, cerebral venous thrombosis, defibrinogenating effect
Cerebral venous thrombosis (CVT) is an uncommon subtype of stroke with a highly variable clinical course including life-threatening deterioration especially with multisinus involvement. Although anticoagulation (heparin and warfarin) is still recommended as the gold standard for CVT treatment per guidelines issued by the American Heart Association (AHA) and American Stroke Society (ASSA) in 2011, and the European Federation of Neurological Societies (EFNS) in 2017, the outcomes of CVT still can include deterioration despite aggressive anticoagulation and mechanical venous thrombectomy (CVT) are invasive and typically used when patients fail anticoagulation. Adjunctive noninvasive therapies are needed to increase the efficacy of anticoagulation for CVT.

Batroxobin is a thrombin-like serine protease extracted from Bothrops atrox moojeni venom. It is a defibrinogenating agent which is more commonly used on cerebral arterial thrombosis. A recent study revealed that batroxobin in combination with anticoagulation may be safe and effective for reducing fibrinogen in cerebral venous circulation and promoting thrombolysis. The authors of the previous study utilized time-of-flight magnetic resonance venography (TOF MRV) in patients who underwent intravenous batroxobin plus anticoagulation, the study identified batroxobin as a promising agent in CVT control. Despite these positive findings, TOF MRV assesses recanalization only by indirect imaging of venous flow perturbation caused by the thrombus; thus, this method may be less specific as it cannot depict the dissolving thrombus and luminal patency within the cerebral vein and venous sinus. Direct visualization of the thrombus itself is a problem overcome by magnetic resonance black-blood thrombus imaging (MRBTI) technique. MRBTI is a 3-dimensional variable flip angle turbo spin echo and is capable of achieving accurate detection of thrombus and patency status in cerebral venous system. Herein, with the help of MRBTI technique, we aimed to further evaluate the efficacy of batroxobin on promoting CVT recanalization.

METHODS

Patients collection

This is a real-world patient registry study performed in accordance with the guidelines of the 1964 Declaration of Helsinki. Given the real-world nature of our study, randomization was not possible. All procedures conducted in this study involving human participants have been approved by the Institutional Ethics Committee (Xuanwu Hospital, Capital Medical University). The informed consents were obtained from the patients before initiating any study-specific procedures. From March 2011 through April 2018, a total of 31 patients who were confirmed as CVT in the neurology department of Xuanwu Hospital, Capital Medical University, were recruited into this study. The diagnosis of CVT was confirmed by MRBTI. The detailed criteria of diagnosis could be seen in the current CVT guidelines. The enrolled patients were screened with the following inclusion and exclusion criteria:

Inclusion criteria: (a) The diagnosis of CVT should be confirmed; (b) Age ranged from 18 to 80; (c) anticoagulation was the main therapeutic strategy in hospital; and (d) MRBTI was finished prior to the treatment and performed again at long-term follow-up.

Exclusion criteria: (a) Patients underwent endovascular treatment or thrombolysis (such as recombinant tissue plasminogen activator and urokinase) prior to the admission or during hospitalization; (b) Subjects without complete data; (c) The levels of baseline plasma fibrinogen were equal to or less than 1 g/L at admission; and (d) Patients were afflicted by other severe diseases.

INTRODUCTION

2 | METHODS

2.1 | Patients collection

2.2 | Intervention and assessment

According to batroxobin use or not, the cohort of patients was grouped into batroxobin (batroxobin in combination with anticoagulation) and control (anticoagulation alone). All of the eligible patients in the two groups underwent standard anticoagulation according to current CVT management guidelines [low molecular weight heparin (LMWH) subcutaneous injection (0.4 mg/kg/h) bridged with warfarin 3 mg/d for 5-7 days, followed by oral warfarin 3 mg/d, to maintain the international normalized ratio (INR) fluctuating between 2 and 3]. In the batroxobin group, all patients underwent intravenous batroxobin after signed an informed consent [batroxobin injection (produced by Beijing Tuobixi Pharmaceutical Co., Ltd., the approval number was H20031074) 10 BU for the first time, followed by 5 BU every other day, for two times, unless the level of fibrinogen dropped to 1.0 g/L or less]. The paradigm aforementioned was also depicted in our previously published study.

MRBTI was used to evaluate the stenosis extent in cerebral venous system in CVT patients. All magnetic resonance tests were conducted on a 3.0-T system (MAGNETOM Verio, Siemens Healthcare, Erlangen, Germany) with a 32-channel head coil for signal reception. Typical imaging parameters included oblique coronal single-slab coverage, repetition time = 800 ms, echo time = 22 ms, matrix = 198 × 192, field of view = 160 × 200 mm², slice thickness = 0.6-1.0 mm, slices = 100-200, and scan time = 6-8 minutes. The venous stenosis extent presented on MRBTI corresponded to the grading criteria in cerebral arteries as normal (<30%), mild (30%-49%), moderate (50%-69%), severe stenosis (70%-90%), and occlusion (100%). In case of multistenosis in one segment, the most severe section was evaluated. Imaging assessment was finished by two independent readers with extensive experience.

2.3 | Outcome evaluation

The recanalization degree on TOF MRV and the degree of the segment-stenosis attenuation on MRBTI were followed up and recorded as the primary outcome. The recanalization degree was graded into four classes, Class 0: complete nonrecanalization; Class 1: partial recanalization of one or more occluded sinuses with improved
collateral flow; Class 2: complete recanalization of one sinus but persistent occlusion of the other sinuses; and Class 3: complete recanalization of all occluded sinuses. Of the four classes, Class 2 and 3 were identified as recanalization, while Class 0 and 1 were defined as nonrecanalization. The stenosis attenuation was ranked into four classes according to the variation of stenosis extent from baseline to follow-up on MRBTI maps (Figure 1), Class 0: exacerbation (thrombus increased); Class 1: no change or mild recovery (thrombus no change or reduced <30%); Class 2: moderate recovery (thrombus reduced to 30%-60%); and Class 3: obvious or complete recovery (thrombus reduced to 60%-100%).

The secondary outcomes comprised the ratio of patients with recanalization measured by TOF MRV, and the ratio of patients with stenosis attenuation, as well as the ratio of segments with stenosis amelioration, and the stenosis extent per involved segments. All of which were assessed by MRBTI, furthermore, the neurological deficits including the National Institute of Health Stroke Scale (NIHSS) scores at discharge, the modified Rankin Scale (mRS) scores at 3 months, and hemorrhage occurrence/aggravation during hospitalization were also recorded. The stenosis attenuation was defined as stenosis with a ≥30% improvement in vessel diameter. The hemorrhage aggravation was an increase of 3 mL or >33% of primary hematoma volume on the follow-up images.²²

### 2.4 Statistical analysis

SPSS 19.0 was used for data analysis. Continuous data following a Gaussian distribution were presented as mean ± standard deviation and analyzed with t test; otherwise, it was expressed as median (interquartile range, IQR) and analyzed with a Mann-Whitney U test. Categorical data were processed by chi-square test (for dichotomous variable) or Mann-Whitney U test (for ordinal dependent variable). For further test, multivariate analyses such as logistic regression model and linear regression models were needed to rule out confounding effects. The results were displayed as an odd ratio (OR) along with 95% confidence interval (95%CI). *P* < 0.05 was considered indicative of statistical significance.

### 3 RESULTS

#### 3.1 Baseline characteristics

A total of 31 subjects were recruited in this study, 21 patients in the batroxobin group and 10 cases in the control group. Thrombus was present in a total of 92 segments (35 transverse sinus, 22 sigmoid sinus, 21 sagittal sinus, 2 deep veins, 1 straight sinus, and 11 cortical veins), among which, 64 segments were in the

---

**FIGURE 1** On MRBTI maps (follow-up vs. baseline), the degree of the segment-stenosis attenuation consists of: A, Class 0: exacerbation (thrombus increased); B, Class 1: no change or mild recovery (thrombus no change or reduced <30%); C, Class 2: moderate recovery (thrombus reduced to 30%-60%); D, Class 3: obvious or complete recovery (thrombus reduced to 60%-100%)
batroxobin group and 28 in the control group. Overall, the average age was 32.8 ± 16.7 years, the mean time from symptom onset to admission was 21.5 ± 16.9 days, the mean hospital stay was 12.7 ± 2.83 days, and the mean imaging follow-up interval was 153 ± 114 days. All subjects were alive during either hospitalization or long-term follow-up, including one patient in the control group who had a cerebral hemorrhage at admission. The baseline data (including demographic, risk factors, imaging assessment, and neurological deficits) were equivalent between the two cohorts, except for hyper-fibrinogen ($P = 0.03$). Details are displayed in Table 1.

### 3.2 Primary outcomes

According to the recanalization criteria previously mentioned using TOF MRV, the recanalization degree at follow-up in batroxobin group was profoundly higher than that in control, regardless of adjusting for confounders (follow-up time and thrombophilia) or not [unadjusted OR (95%CI) of 8.22 (1.73-39.1), $P < 0.01$; adjusted OR (95%CI) of 8.10 (1.61-40.7), $P = 0.01$]. Further subgroup analysis of patients with normal fibrinogen (1 g/L < fibrinogen<4 g/L) revealed the batroxobin group again had better recanalization degree [OR (95% CI) 5.64 (1.06-30.0) and adjusted OR (95%CI) was of 5.65 (0.95-33.4)]. Hyper-fibrinogen levels were included only in batroxobin group in this study.

When evaluated by MRBTI follow-up, segment stenosis reversed more profoundly in batroxobin group compared with control [unadjusted OR (95%CI) of 2.91 (1.25-6.80), $P = 0.01$; adjusted OR (95%CI) of 4.48 (1.69-11.9), $P < 0.01$]. Among the patients with normal fibrinogen, the segment-stenosis attenuation in batroxobin group was more obvious than that in control [OR (95%CI) of 3.35 (1.33-8.43), $P = 0.01$; adjusted OR (95%CI) of 5.08 (1.67-15.5), $P < 0.01$]. All of above are displayed in Figure 2.

### 3.3 Imaging outcomes

Of the 31 subjects enrolled, 15/21 cases (71.4%) in the batroxobin group displayed recanalization on TOF MRV, while only 3/10 (30.0%) of the control patients had similar findings [unadjusted OR (95%CI) of 5.84 (1.12-30.4); adjusted OR (95%CI) of 6.05 (1.06-34.7)]. Moreover, there were 90.5% (19/21) cases in batroxobin group presenting with stenosis improving ≥30% on the follow-up MRBTI maps, while only 60.0% (6/10) in control showed stenosis improvement on imaging [unadjusted OR (95%CI) of 6.33 (0.92-43.6); adjusted OR (95%CI) of 26.4 (1.10-635)]. Similarly, of the 92 involved stenotic segments, the ratio of segments with stenosis extent improvement (≥30%) was 68.8% (44/64) in batroxobin group, but 46.4% (13/28) in control [unadjusted OR (95%CI) of 2.54 (1.02-6.32); adjusted OR (95%CI) of 4.52 (1.48-13.8)]. In contrast, there was no difference on stenosis extent in the diseased

### Table 1 Characteristics of involved subjects at baseline

|                             | Batroxobin, n = 21 | Control, n = 10 | P-value  |
|-----------------------------|--------------------|----------------|----------|
| **Demographic**             |                    |                |          |
| Gender (Female/Male)        | 12/9               | 4/6            | 0.458    |
| Age (y)                     | 29.8 ± 14.5        | 39.2 ± 21.5    | 0.226    |
| **Clinical appearances**    |                    |                |          |
| Coma                        | 2 (9.5%)           | 0 (0.0%)       | 1.000    |
| Seizures                    | 12 (57.1%)         | 3 (30.0%)      | 0.252    |
| Focal signs                 | 9 (42.9%)          | 2 (20.0%)      | 0.262    |
| Hyper-fibrinogen condition  | 9 (42.9%)          | 0 (0.0%)       | 0.030    |
| NIHSS scores at admission   | 0.00 (0.00, 2.00)  | 0.00 (0.00, 2.50) | 0.539 |
| mRS scores at admission     | 3.00 (2.00, 3.00)  | 2.00 (1.00, 4.00) | 0.370 |
| Time of hospital stay (d)   | 13.14 ± 2.89       | 11.90 ± 2.64   | 0.260    |
| Time from symptom onset to admission (d) | 19.84 ± 15.28 | 24.60 ± 20.04 | 0.480    |
| Follow-up time              | 132.67 ± 113.23    | 194.50 ± 110.58 | 0.163 |
| Intracerebral hemorrhage    | 0 (0.0%)           | 1 (10.0%)      | 0.323    |
| **Risk factors**            |                    |                |          |
| Pregnancy                   | 3 (14.3%)          | 1 (10.0%)      | 1.000    |
| Infection                   | 3 (14.3%)          | 1 (10.0%)      | 1.000    |
| Oral contraceptives         | 2 (9.5%)           | 0 (0.0%)       | 1.000    |
| Hyperhomocysteinemia        | 4 (19.0%)          | 0 (0.0%)       | 0.277    |
| Thrombophilia               | 9 (42.9%)          | 3 (30.0%)      | 0.697    |
| Hematologic disorders       | 2 (9.5%)           | 3 (30.0%)      | 0.296    |
| Systemic diseases           | 2 (9.5%)           | 0 (0.0%)       | 1.000    |
segments at baseline between the two groups [batroxobin versus control: unadjusted OR (95%CI) of 0.94 (0.43-2.08); adjusted OR (95%CI) of 0.66 (0.28-1.57)]. The results are presented in Table 2.

3.4 | Neurological deficits

No difference was detected between the two groups regarding both NIHSS scores at discharge and mRS scores at 3 months for the batroxobin group versus control group: OR (95%CI) for NIHSS score improvement was of 0.71 (0.12-4.26) and 0.61 (0.34-1.10) after adjustment and OR (95%CI) for mRS scores was of 1.10 (0.27-4.49) and 1.14 (0.26-5.04) after adjustment. There were no cerebral hemorrhage events (emerging hemorrhage or aggravating hemorrhage) during patient hospitalization. The results aforementioned are shown in Table 3.

3.5 | Thrombus outcomes in different venous sinuses

The stenosis extent and the ratio of segments with stenosis attenuation in different venous sinuses involved at baseline were not statistically different between the two groups. The degree of segment-stenosis attenuation in superior sagittal sinus in batroxobin group was more remarkable than that in control [adjusted OR (95%CI) of 18.0 (1.26-257), P = 0.03]; however, these results were not seen in other venous sinus involvement.

4 | DISCUSSION

Coagulation abnormalities are present by a number of conditions, including surgery, pregnancy, puerperium, trauma, anticardiolipin syndrome, malignancy, and thrombophilia. These conditions are considered to be involved mechanisms contributing to CVT.1,2 To overcome the imbalance in hypercoagulability in CVT, the standard therapy is anticoagulation.1,2 At times anticoagulation alone is not sufficient to reverse the disease process of CVT despite favorable clinical efficacy.2,23,24 We sought to identify adjunctive noninvasive therapies for multitarget treatments to coagulation-fibrinolysis pathways. Our hope was to identify a synergistic agent that can be utilized with anticoagulation for CVT recanalization.

As we all know, only with the help of AT-III, can heparin and LMWH inhibit the activation of Factor Ila and Factor Xa, respectively.25 For this reason, heparin-based therapies may be not...
suitable for the CVT patients with AT-III deficiency. Furthermore, although heparinoids have the capability of preventing further thrombus extension, existing thrombus is not readily lysed.\textsuperscript{26-28} Given the disadvantages of anticoagulation, it is proposed that thrombolysis in CVT patients may produce desirable clinical benefits.\textsuperscript{6,8} Thrombolytic agents directly influence the fibrinolytic system and convert plasminogen to plasmin, which eventually removes the blood clot in the circulation. Although local thrombolysis has shown benefits in some CVT cases, this invasive therapy inevitably faces a risk of hemorrhagic transformation along with poor clinical outcomes.\textsuperscript{9} Invasive strategies such as local thrombolysis and mechanical thrombectomy are limited to observational studies.\textsuperscript{6,10} Therefore, endovascular mechanical thrombectomy or thrombolysis will be considered only at the condition of CVT-associated clinical deterioration.

Batroxobin, an agent widely used in arterial thrombosis, binds fibrinogen with 10-fold affinity as compared with thrombin, followed by a decrease in the level of fibrinogen in the circulation, resulting

---

**TABLE 2** Secondary outcomes in the 31 patients

| Secondary outcomes                          | Batroxobin group (Patient/segment, n = 21/64) | Control group (Patient/segment, n = 10/28) | Unadjusted OR (95%CI) | Adjusted OR (95%CI) |
|---------------------------------------------|-----------------------------------------------|-------------------------------------------|-----------------------|---------------------|
| Follow-up evaluation on TOF MRV             |                                               |                                           |                       |                     |
| Patients with recanalization, n (%)         | 15 (71.4)                                     | 3 (30.0)                                  | 5.84 (1.12-30.40)     | 6.05 (1.06-34.69)   |
| Follow-up evaluation on MRBTI               |                                               |                                           |                       |                     |
| Patients with stenosis relieved, n (%)      | 19 (90.5)                                     | 6 (60.0)                                  | 6.33 (0.92-43.62)     | 26.36 (1.10-634.65) |
| Segments with stenosis relieved, n (%)      | 44 (68.8)                                     | 13 (46.4)                                 | 2.54 (1.02-6.32)      | 4.52 (1.48-13.75)   |
| Stenosis extent, median (IQR)               | 2.00 (1.00, 3.00)                             | 2.00 (1.00, 3.00)                         | 0.94 (0.43-2.08)      | 0.66 (0.28-1.57)    |

---

**TABLE 3** The follow-up changes of thrombus on each subtype of segments in batroxobin group vs control

| Afflicted patients (num.) | Stenosis extent | Segments with stenosis relieved | Stenosis attenuation degree |
|---------------------------|-----------------|---------------------------------|----------------------------|
| Superior sagittal sinus   | 0.99 (0.12-8.43) | 11.68 (0.66-206.72)             | 17.98 (1.26-256.91)        |
| Inferior sagittal sinus   | —               | —                               | —                          |
| Left transverse sinus     | 0.50 (0.06-4.54) | 1.24 (0.09-16.30)               | 2.86 (0.28-29.16)          |
| Right transverse sinus    | 0.52 (0.07-3.77) | 12.49 (0.39-395.63)             | 7.28 (0.38-140.97)         |
| Left sigmoid sinus        | 9.84 (0.47-204.00) | 5.37 (0.04-709.33)                | 2.72 (0.21-35.75)          |
| Right sigmoid sinus       | 0.60 (0.03-10.65) | 4.40 (0.13-145.99)               | 2.33 (0.07-79.68)          |
| Deep veins                | —               | —                               | —                          |
| Straight sinus            | —               | —                               | —                          |
| Cortical veins            | 0.10 (0.00-6.38) | 0.32 (0.01-12.94)               | 4.38 (0.08-227.33)         |

---

Binary data or ordinal data were analyzed through a binary or ranked logistic regression model to adjust for confounding effects, while continuous data analysis was performed with a linear regression model to adjust for confounding effects. The confounding factors included follow-up time and thrombophilia in the multivariate analyses of patients with stenosis relieved, segments with stenosis relieved and stenosis extent, and NIHSS at admission in the analysis of NIHSS at discharge and mRS at 6 mo.

\textsuperscript{*}P < 0.05.

\textsuperscript{**}P < 0.01.

---

**TABLE 3** The follow-up changes of thrombus on each subtype of segments in batroxobin group vs control

| Afflicted patients (num.) | Stenosis extent | Segments with stenosis relieved | Stenosis attenuation degree |
|---------------------------|-----------------|---------------------------------|----------------------------|
| Superior sagittal sinus   | 0.99 (0.12-8.43) | 11.68 (0.66-206.72)             | 17.98 (1.26-256.91)        |
| Inferior sagittal sinus   | —               | —                               | —                          |
| Left transverse sinus     | 0.50 (0.06-4.54) | 1.24 (0.09-16.30)               | 2.86 (0.28-29.16)          |
| Right transverse sinus    | 0.52 (0.07-3.77) | 12.49 (0.39-395.63)             | 7.28 (0.38-140.97)         |
| Left sigmoid sinus        | 9.84 (0.47-204.00) | 5.37 (0.04-709.33)                | 2.72 (0.21-35.75)          |
| Right sigmoid sinus       | 0.60 (0.03-10.65) | 4.40 (0.13-145.99)               | 2.33 (0.07-79.68)          |
| Deep veins                | —               | —                               | —                          |
| Straight sinus            | —               | —                               | —                          |
| Cortical veins            | 0.10 (0.00-6.38) | 0.32 (0.01-12.94)               | 4.38 (0.08-227.33)         |

---

Ranked logistic regression model for stenosis extent and stenosis attenuation degree, and binary logistic regression model for number of segments with stenosis relieved are used to adjust for confound effect (follow-up time and thrombophilia). The results are expressed as adjusted OR (95% CI).
Moreover, it has been demonstrated that batroxobin could prompt the production of tissue plasminogen activator (tPA), mitigate the activation of tissue plasminogen inhibitor (PAI), impede platelet activation, and reduce blood viscosity improving microcirculation. The coagulation-fibrinolysis pathways and the target of the aforementioned interventions are presented in Figure 3.

In the previous publication, it has been verified that batroxobin may be a promising adjunct for standard anticoagulation strategy of CVT control; however, the MRV/CTV utilized was a rough imaging technique for evaluating the follow-up imaging outcomes. In order to further enhance the accuracy of the assessment and provide a more convincing conclusion, we utilized MRBTI as the main imaging evaluation tool in this study. Yang et al found MRBTI can confirm the diagnosis of CVT with a high accuracy by which thrombus in the veins/sinuses can be directly visualized. Instead of directly imaging thrombus of MRBTI, MRV relies on the presentation of altered blood flow in veins, which may not express the real luminal patency and compromise the evaluating confidence to some extent.

In agreement with the previous results, this cohort of batroxobin-treated patients experienced improved recanalization rates and degree on TOF MRV and MRBTI. The reduction in stenosis extent on MRBTI in batroxobin group was more significant than that in control. Among the patients with normal fibrinogen, batroxobin in combination with anticoagulation still exhibited more benefit than anticoagulation alone. Although we cannot perform comparisons among patients with high fibrinogen levels, the recent study showed the important role of batroxobin in CVT with high fibrinogen levels. The stenosis improvement rates on MRBTI maps were more remarkable in the batroxobin group compared to the control group. These results indicate some degree of lysis is taking place or enhanced vessel remodeling in the batroxobin group. Although the stenosis extent at follow-up between the two groups did not reach a significant difference, changes in the stenosis extent after intravenous batroxobin showed strong trends on dissolving thrombus. The MRBTI map gave us direct visualization of clot elimination with nonionizing radiation suggesting this may be a new noninvasive accurate way of following CVT patients.

The elevation of D-dimer (more than 20-fold of baseline) and reduction in fibrinogen after batroxobin use presented in the previous study.
provide a convincing demonstration that fibrinolysis and thrombolysis induced by batroxobin can dissolve CVT thrombus.\textsuperscript{16} Subgroup analysis based on the nine subtypes of venous system segments was also performed. Only the superior sagittal segment displayed remarkable stenosis reduction in batroxobin group compared with control. Small sample sizes constricted the test power, despite which, we still thought that the thrombus in superior sagittal segment might be more susceptible to defibrase drugs. This may be explained by more drug reaching this area first given normal drainage patterns.

NIHSS scores and mRS scores at discharge and 6 months were equivalent between the patients with batroxobin use and controls in the previous study. Only discharge NIHSS scores were significantly better in batroxobin group.\textsuperscript{16} The current study revealed no significant differences in NIHSS or mRS at follow-up. As opposed to cerebrovascular occlusion, the neurological deficits mediated by CVT can be more asymptomatic, the NIHSS scores and mRS scores may not accurately reflect the differences in clinical outcomes of patients with CVT (especially in regard to headaches, papilledema, venous hypertension all related to chronic venous drainage insufficiency). One patient suffered from cerebral hemorrhage at admission, after anticoagulation treatment, the hematoma did not further enlarge. No other hemorrhages were noted in this study. We cannot conclude on the safety of batroxobin in this study, but in the previously published study, the risk of hemorrhage in batroxobin group was lower than control but with nonstatistical significance.\textsuperscript{16} Other previous reports regarding batroxobin treating cerebral arterial disease have found a low risk of batroxobin-induced hemorrhage.\textsuperscript{33,34} Therefore, we believe that using batroxobin in CVT patients is safe.

There were some limitations to this study. Our small sample size renders the study underpowered and restricts the conclusion reliability, due to which, the multivariate analysis could not involve enough relative confounding factors and subgroup analysis may not suffice achieving convincing results. Large randomized trials would be difficult with such a rare disease process. Despite this, a well-designed large sample size trial is needed to further evaluate. The present study is a real-world experience, and this means it cannot be randomized and controlled. The low-quality design may affect the study conclusion. The treatment group was assigned in accordance with the patients consent and wishes to be treated with this novel drug and controls identified. Cohort studies such as ours can be valuable despite not being randomized. Because most of the enrolled patients only conducted two times of MRBTI in this study, more sequential MRBTI imaging would be necessary to evaluate if batroxobin was able to accelerate the recanalization in CVT patients. Although the follow-up time between the two groups did not reach difference and multivariate analysis had adjusted for this confounding factor, the bias still existed in this study and the conclusions need to be further determined.

5 | CONCLUSION

With the help of MRBTI, we notice that batroxobin may promote recanalization and attenuate venous sinus stenosis in CVT. Considering the limitations of this study, multicenter, well-designed, large sample size prospective trials are needed to further verify this conclusion.

ACKNOWLEDGMENTS

We would like to thank all patients and doctors who participated in this study for their cooperation. This study was sponsored by the National Key R&D Program of China (2017YFC1308400), the National Natural Science Foundation (81371289), and the Project of Beijing Municipal Top Talent for Healthy Work of China (2014-2015).

CONFLICT OF INTEREST

All authors report no conflicts of interest.

ORCID

Jia-yue Ding https://orcid.org/0000-0003-3562-2187
Da Zhou https://orcid.org/0000-0003-1376-4213
Ran Meng https://orcid.org/0000-0001-8452-8758

REFERENCES

1. Ferro JM, Bousser MG, Canhão P, et al. European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis - endorsed by the European Academy of Neurology. Eur J Neurol. 2017;24:1203-1213.
2. Saposnik G, Barinagarrementeria F, Brown RD, et al. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:1158-1192.
3. Ding J, Zhou D, Geng T, et al. to predict visual deterioration according to the degree of intracranial hypertension in patients with cerebral venous sinus thrombosis. Eur Neurol. 2018;80:28-33.
4. Einhäupl KM, Villringer A, Meister W, et al. Heparin treatment in sinus venous thrombosis. Lancet. 1991;338:597-600.
5. Ferro JM, Canhão P, Stam J, Bousser MG, Barinagarrementeria F. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke. 2004;35:664-670.
6. Canhão P, Falcão F, Ferro JM, Thrombolitics for cerebral sinus thrombosis: a systematic review. Cerebrovasc Dis. 2003;15:159-166.
7. Kim SY, Suh JH. Direct endovascular thrombolytic therapy for dural sinus thrombosis: infusion of alteplase. AJNR Am J Neuroradiol. 1997;18:639-645.
8. Dentali F, Squizzato A, Gianni M, et al. Safety of thrombolysis in cerebral venous thrombosis. A systematic review of the literature. Thromb Haemost. 2010;104:1055-1062.
9. Bousser MG. Cerebral venous thrombosis: nothing, heparin, or local thrombolysis. Stroke. 1999;30:481-483.
10. Fargen KM, Hoh BL. Aggressive surgical management of dural venous sinus thrombosis: a review of the literature. World Neurosurg. 2014;82:e61-63.
11. Fukutake K, Fujimaki M, Nagasawa H, Kato M. Clinico-pharmacological observations of batroxobin (Defibrase) administered to normal human adults (author’s transl). Nihon Ketsueki Gakkai Zasshi. 1981;44:1178-1194.
12. Yitao H, Kefu M, Bingshan T, et al. Effects of batroxobin with continuous transcranial Doppler monitoring in patients with acute
cerebral stroke: a randomized controlled trial. Echocardiography. 2014;31:1283-1292.

13. Xu G, Liu X, Zhu W, Yin Q, Zhang R, Fan X. Feasibility of treating hyperfibrinogenemia with intermittently administered batroxobin in patients with ischemic stroke/transient ischemic attack for secondary prevention. Blood Coagul Fibrinolysis. 2007;18:193-197.

14. Wu W, Kuang P, Li Z. Effect of batroxobin on neuronal apoptosis during focal cerebral ischemia and reperfusion in rats. J Tradit Chin Med. 2001;21:136-140.

15. Wang J, Zhu YQ, Li MH, et al. Batroxobin plus aspirin reduces restenosis after angioplasty for arterial occlusive disease in diabetic patients with lower-limb ischemia. J Vasc Interv Radiol. 2011;22:987-994.

16. Ding J, Zhou D, Hu Y, et al. The efficacy and safety of Batroxobin in combination with anticoagulation on cerebral venous sinus thrombosis. J Thromb Thrombolysis. 2018;46:371-378.

17. Chiewvit P, Piyapittayanan S, Poungvarin N. Cerebral venous thrombosis: diagnosis dilemma. Neurol Int. 2011;3:e13.

18. Yang Q, Duan J, Fan Z, et al. Early detection and quantification of cerebral venous thrombosis by magnetic resonance black-blood thrombus imaging. Stroke. 2016;47:404-409.

19. Liu Q, Huang J, Degnan AJ, et al. Comparison of high-resolution MRI with CT angiography and digital subtraction angiography for the evaluation of middle cerebral artery atherosclerotic steno-occlusive disease. Int J Cardiovas Imaging. 2013;29:1491-1498.

20. Jeon JS, Sheen SH, Hwang GJ, Kim HC, Kwon BJ. Feasibility of intravenous flat panel detector CT angiography for intracranial arterial stenosis. AJNR Am J Neuroradiol. 2013;34:129-134.

21. Qureshi AI. A classification scheme for assessing recanalization and collateral formation following cerebral venous thrombosis. J Vasc Interv Radiol. 2010;3:1-2.

22. Dowlatshahi D, Demchuk AM, Flaherty ML, Ali M, Lyden PL, Smith EE. Defining hematoma expansion in intracerebral hemorrhage: relationship with patient outcomes. Neurology. 2011;76:1238-1244.

23. Meng R, Ji X, Wang X, Ding Y. The etiologies of new cases of cerebral venous sinus thrombosis reported in the past year. Intractable Rare Dis Res. 2012;1:23-26.

24. de Bruijn SF, Stam J. Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis. Stroke. 1999;30:484-488.

25. Coutinho JM, de Bruijn SF, deVeber G, Stam J. Anticoagulation for cerebral venous sinus thrombosis. Stroke. 2012;43:e41-e42.

26. Bounameaux H, Camm AJ. Edoxaban: an update on the new oral direct factor Xa inhibitor. Drugs. 2014;74:1209-1231.

27. Barnwell SL, Higashida RT, Halbach VV, Dowd CF, Hieshima GB. Direct endovascular thrombolytic therapy for dural sinus thrombosis. Neurosurgery. 1991;28:135-142.

28. Bousser MG, Chiras J, Bories J, Castaigne P. Cerebral venous thrombosis—a review of 38 cases. Stroke. 1985;16:199-213.

29. Klöcking HP, Markwardt F, Gütter J. On the mechanism of batroxobin-induced fibrinolysis. Pharmacaz. 1989;44:504-505.

30. Lees KR. Thrombolysis. Br Med Bull. 2000;56:389-400.

31. Mayberg MR, Furlan A. Ancrod—is snake venom an antidote for stroke. JAMA. 2000;283:2440-2442.

32. Freischlag JA, Colburn MD, Quiñones-Baldrich WJ, Moore WS. Heparin, urokinase, and ancrod alter neutrophil function. J Vasc Surg. 1992;16:565-572; discussion 572-574.

33. Tomaru T, Nakamura F, Miwa AY, et al. Antithrombin and thrombolytic effects of a new antithrombin agent: angioscopic and angiographic comparison with heparin or batroxobin. J Interv Cardiol. 1994;7:409-419.

34. Tomaru T, Nakamura F, Aoki N, Sakamoto Y, Omata M, Uchida Y. Local treatment with an antithrombotic drug reduces thrombus size in coronary and peripheral thrombosed arteries. Heart Vessels. 1996;11:133-144.